Urothelial carcinogenesis in the urinary bladder of rats treated with naveglitazar, a gamma-dominant PPAR alpha/gamma agonist: lack of evidence for urolithiasis as an inciting event.
about
Peroxisome proliferator-activated receptors and their ligands: nutritional and clinical implications--a reviewMinireview: Challenges and opportunities in development of PPAR agonistsThiazolidinediones and associated risk of bladder cancer: a systematic review and meta-analysisPeroxisome Proliferator-Activated Receptors and the Heart: Lessons from the Past and Future Directions.Rat Urinary Bladder Carcinogenesis by Dual-Acting PPARalpha + gamma AgonistsPPAR agonists for the treatment of cardiovascular disease in patients with diabetes.Thiazolidinedione safety.Peroxisome proliferator-activated receptor agonists and bladder cancer: lessons from animal studies.A review of the efficacy and safety of oral antidiabetic drugsScientific Evidence and Controversies About Pioglitazone and Bladder Cancer: Which Lessons Can Be Drawn?Refocusing Peroxisome Proliferator Activated Receptor-α: A New Insight for Therapeutic Roles in Diabetes.Thiazolidinedione drugs in the treatment of type 2 diabetes mellitus: past, present and future.Diabetes drugs and the incidence of solid cancers: a survey of the current evidence.PPAR alpha and PPAR gamma coactivation rapidly induces Egr-1 in the nuclei of the dorsal and ventral urinary bladder and kidney pelvis urothelium of rats.Neoplastic and non-neoplastic changes in F-344 rats treated with Naveglitazar, a gamma-dominant PPAR alpha/gamma agonist.Raf inhibition causes extensive multiple tissue hyperplasia and urinary bladder neoplasia in the rat.
P2860
Q26866784-F115BA72-8172-4E81-B566-1504DC95622CQ33631921-2F4BAA3E-42AD-435A-800F-0D09A98FC750Q34065266-AEB29BEA-16C8-4D96-9B59-9149F580E995Q36261125-2075278A-B081-42C9-BCE1-FAF578B5E180Q37077098-40D1E3FC-857D-4B32-9AD1-D5846952E873Q37996437-2D27C8E7-99FB-4349-9D0C-C74296E96C8EQ38012205-8A0C15DC-2FBD-4E4C-AFD4-84D6DA361106Q38061184-CE64F9A9-7750-4182-A91A-0D566E6D329BQ38067491-5D1BA281-9B18-4278-90B1-804E701F4C46Q38122640-BFD5F2D3-1300-42FC-8674-5A70FD19998DQ38160494-D1732F16-D01D-4BC8-AC37-85361C57E38DQ38641190-F5E593C7-1001-4D5E-9E17-8F90858907E6Q38651175-A1F98FCA-6083-4D68-A80F-386AE12BAC2FQ43222810-10279681-6743-4DAD-9C09-BDB144A8A391Q43287595-06738A33-6736-4E65-AFAE-498CF6F1CBBBQ51449752-B74387D1-BD70-48D4-81CB-2EF3ACB8B85D
P2860
Urothelial carcinogenesis in the urinary bladder of rats treated with naveglitazar, a gamma-dominant PPAR alpha/gamma agonist: lack of evidence for urolithiasis as an inciting event.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
Urothelial carcinogenesis in t ...... ithiasis as an inciting event.
@en
Urothelial carcinogenesis in t ...... ithiasis as an inciting event.
@nl
type
label
Urothelial carcinogenesis in t ...... ithiasis as an inciting event.
@en
Urothelial carcinogenesis in t ...... ithiasis as an inciting event.
@nl
prefLabel
Urothelial carcinogenesis in t ...... ithiasis as an inciting event.
@en
Urothelial carcinogenesis in t ...... ithiasis as an inciting event.
@nl
P2093
P2860
P356
P1476
Urothelial carcinogenesis in t ...... ithiasis as an inciting event.
@en
P2093
Alric Lopez-Martinez
Gerald G Long
Sandra R Eldridge
Sandy L White
Thomas E Ryan
Vincent L Reynolds
P2860
P304
P356
10.1177/0192623307311757
P407
P577
2008-02-01T00:00:00Z